RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020

Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions...

Full description

Bibliographic Details
Main Authors: Elizabeth R. Packnett, Isabelle H. Winer, Heather Larkin, Abiola Oladapo, Tara Gonzales, Matthew Wojdyla, Mitchell Goldstein, Vincent C. Smith
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
respiratory syncytial virus
respiratory tract infections
infant
premature
pre-exposure prophylaxis
pediatric hospitalization
Online Access:http://dx.doi.org/10.1080/21645515.2022.2140533

Internet

http://dx.doi.org/10.1080/21645515.2022.2140533

Similar Items